CABALETTA BIO, INC. Increase Decrease In Operating Lease Liability
CABALETTA BIO, INC. (CABA) reported Increase Decrease In Operating Lease Liability of -$2.11 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- CABALETTA BIO, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.06M.
- CABALETTA BIO, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.06M.
- CABALETTA BIO, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.06M, a 237.99% decline year-over-year.
- CABALETTA BIO, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.06M.
- CABALETTA BIO, INC. increase decrease in operating lease liability for fiscal 2025 was -$4.23M.
- CABALETTA BIO, INC. increase decrease in operating lease liability for fiscal 2024 was -$3.29M.
- CABALETTA BIO, INC. increase decrease in operating lease liability for fiscal 2023 was -$2.46M.
- CABALETTA BIO, INC. increase decrease in operating lease liability for fiscal 2022 was -$2.91M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.11M 10-Q · filed 2026-08-13 | -$3.17M derived: sum of 3 quarters · filed 2026-08-13 | -$4.23M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$1.06M 10-Q · filed 2026-05-14 | -$2.11M derived: sum of 2 quarters · filed 2026-05-14 | -$3.17M derived: sum of 3 quarters · filed 2026-05-14 | -$4.23M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$2.11M derived: sum of 2 quarters · filed 2026-03-23 | -$3.17M derived: sum of 3 quarters · filed 2026-08-13 | -$4.23M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$2.11M derived: sum of 2 quarters · filed 2026-08-13 | -$3.17M 10-Q · filed 2025-11-10 | -$2.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.11M 10-Q · filed 2026-08-13 | -$1.35M derived: sum of 3 quarters · filed 2026-08-13 | -$3.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.06M 10-Q · filed 2026-05-14 | -$291.00K derived: sum of 2 quarters · filed 2026-05-14 | -$2.13M derived: sum of 3 quarters · filed 2026-05-14 | -$3.10M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $766.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$1.07M derived: sum of 2 quarters · filed 2026-03-23 | -$2.04M derived: sum of 3 quarters · filed 2026-03-23 | -$3.29M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$2.81M derived: sum of 2 quarters · filed 2025-11-10 | -$4.06M 10-Q · filed 2025-11-10 | -$4.80M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$968.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$2.22M 10-Q · filed 2025-08-07 | -$2.97M derived: sum of 3 quarters · filed 2025-08-07 | -$3.54M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$1.25M 10-Q · filed 2025-05-15 | -$2.00M derived: sum of 2 quarters · filed 2025-05-15 | -$2.57M derived: sum of 3 quarters · filed 2025-05-15 | -$3.14M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$747.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$1.32M derived: sum of 2 quarters · filed 2025-03-31 | -$1.89M derived: sum of 3 quarters · filed 2025-03-31 | -$2.46M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$570.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$1.14M derived: sum of 2 quarters · filed 2024-11-14 | -$1.71M 10-Q · filed 2024-11-14 | -$4.62M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$569.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.14M 10-Q · filed 2024-08-08 | -$4.05M derived: sum of 3 quarters · filed 2024-08-08 | -$4.05M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$570.00K 10-Q · filed 2024-05-15 | -$3.48M derived: sum of 2 quarters · filed 2024-05-15 | -$3.48M derived: sum of 3 quarters · filed 2024-05-15 | -$3.48M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$2.91M derived: sum of 2 quarters · filed 2024-03-21 | -$2.91M derived: sum of 3 quarters · filed 2024-03-21 | -$2.91M 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |